Table 4.
Clinicopathological characteristics according to risk groups based on HRS in the development cohort.
| Characteristics | High-Risk (n = 154) | Low-Risk (n = 154) | p-Value |
|---|---|---|---|
| Age (means ± standard deviations) | 50.8 ± 11.1 | 51.6 ± 9.9 | 0.494 |
| T stage | <0.001 | ||
| 1 | 62 (40.3) | 125 (81.2) | |
| 2 | 88 (57.1) | 24 (15.6) | |
| 3 | 3 (2.0) | 4 (2.6) | |
| 4 | 1 (0.7) | 1 (0.7) | |
| N stage | <0.001 | ||
| 0 | 66 (42.9) | 123 (79.9) | |
| 1 | 68 (44.2) | 30 (19.5) | |
| 2 | 13 (8.4) | 1 (0.7) | |
| 3 | 7 (4.6) | 0 (0.0) | |
| Histologic grade | <0.001 | ||
| 1 | 13 (8.4) | 69 (44.8) | |
| 2 | 79 (51.3) | 74 (48.1) | |
| 3 | 62 (40.3) | 11 (7.1) | |
| Internal enhancement | 0.060 | ||
| Homogeneous | 11 (7.1) | 17 (11.0) | |
| Heterogeneous | 96 (62.3) | 107 (69.5) | |
| Rim enhancement | 47 (30.5) | 30 (19.45) | |
| Mass shape | 0.102 | ||
| Round | 10 (6.5) | 14 (9.1) | |
| Oval | 8 (5.2) | 17 (11.0) | |
| Irregular | 136 (88.3) | 123 (79.9) | |
| Mass margin | 0.088 | ||
| Circumscribed | 5 (3.3) | 12 (7.8) | |
| Not circumscribed | 149 (96.8) | 142 (92.2) | |
| Pathologic type | 0.308 | ||
| IDC | 145 (94.2) | 140 (90.9) | |
| ILC | 6 (3.9) | 6 (3.9) | |
| Others | 3 (2.0) | 8 (5.2) | |
| Lymphovascular invasion | <0.001 | ||
| Positive | 75 (48.7) | 15 (9.7) | |
| Negative | 79 (51.3) | 139 (90.3) | |
| Extensive intraductal component | 0.897 | ||
| Positive | 40 (26.0) | 41 (26.6) | |
| Negative | 114 (74.0) | 113 (73.4) | |
| ER | <0.001 | ||
| Positive | 94 (61.0) | 150 (97.4) | |
| Negative | 60 (39.0) | 4 (2.6) | |
| PR | <0.001 | ||
| Positive | 79 (51.3) | 139 (90.3) | |
| Negative | 75 (48.7) | 15 (9.7) | |
| p53 | <0.001 | ||
| Positive | 63 (40.9) | 33 (21.4) | |
| Negative | 91 (59.1) | 121 (78.6) | |
| HER2 | 0.001 | ||
| Positive | 41 (26.6) | 18 (11.7) | |
| Negative | 113 (73.4) | 136 (88.3) | |
| Ki-67 | <0.001 | ||
| ≥20% | 119 (77.3) | 25 (16.2) | |
| <20% | 35 (22.7) | 129 (83.8) | |
| Adjuvant chemotherapy | <0.001 | ||
| No | 23 (14.9) | 87 (56.5) | |
| Yes | 131 (85.1) | 67 (43.5) | |
| Adjuvant radiation therapy | 0.001 | ||
| No | 46 (29.9) | 21 (13.6) | |
| Yes | 108 (70.1) | 133 (86.4) | |
| Adjuvant endocrine therapy | <0.001 | ||
| No | 57 (37.0) | 6 (3.9) | |
| Yes | 97 (63.0) | 148 (96.1) | |
| HRS * | 1.188 ± 0.208 | 0.896 ± 0.258 | <0.001 |
Unless otherwise noted, data are numbers of patients and percentages are in parentheses. * Data are presented as mean ± standard deviation.